MBRX Moleculin Biotech Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MBRX

Price (delayed)

$5.02

Market cap

$11.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$15.07

Enterprise value

-$11.89M

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. ...

Highlights
MBRX's debt is up by 41% year-on-year but it is down by 4.4% since the previous quarter
MBRX's quick ratio has dropped by 61% year-on-year and by 45% since the previous quarter
The company's equity has shrunk by 50% YoY and by 26% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.moleculin.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of MBRX
Market
Shares outstanding
2.23M
Market cap
$11.18M
Enterprise value
-$11.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$29.77M
EBITDA
-$29.64M
Free cash flow
-$24.23M
Per share
EPS
-$15.07
Free cash flow per share
-$12.26
Book value per share
$13.12
Revenue per share
$0
TBVPS
$13.7
Balance sheet
Total assets
$38.22M
Total liabilities
$12.14M
Debt
$474,000
Equity
$26.07M
Working capital
$19.46M
Liquidity
Debt to equity
0.02
Current ratio
3.86
Quick ratio
3.46
Net debt/EBITDA
0.78
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-67.7%
Return on equity
-80.9%
Return on invested capital
N/A
Return on capital employed
-94.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MBRX stock price

How has the Moleculin Biotech stock price performed over time
Intraday
-2.14%
1 week
5.24%
1 month
-4.38%
1 year
-56.25%
YTD
-61.01%
QTD
-15.06%

Financial performance

How have Moleculin Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.63M
Net income
-$29.77M
Gross margin
N/A
Net margin
N/A
MBRX's net income is down by 13% since the previous quarter and by 2.6% year-on-year
MBRX's operating income is down by 7% from the previous quarter but it is up by 3.3% YoY

Growth

What is Moleculin Biotech's growth rate over time

Valuation

What is Moleculin Biotech stock price valuation
P/E
N/A
P/B
0.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 11% since the previous quarter
MBRX's price to book (P/B) is 74% lower than its 5-year quarterly average of 1.5 and 35% lower than its last 4 quarters average of 0.6
The company's equity has shrunk by 50% YoY and by 26% QoQ

Efficiency

How efficient is Moleculin Biotech business performance
The company's return on equity has shrunk by 74% YoY and by 33% QoQ
Moleculin Biotech's return on assets has shrunk by 60% YoY and by 26% QoQ

Dividends

What is MBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MBRX.

Financial health

How did Moleculin Biotech financials performed over time
The total liabilities has surged by 177% since the previous quarter and by 132% year-on-year
MBRX's quick ratio has dropped by 61% year-on-year and by 45% since the previous quarter
MBRX's debt is 98% smaller than its equity
The debt to equity has soared by 100% from the previous quarter and by 100% YoY
The company's equity has shrunk by 50% YoY and by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.